Clinical trials: Opioid-Induced Disorders
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design.
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- STRIDE (NCT01550341)
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Opioid Dependence, Craving
tDCS to Decrease Opioid Relapse (UG3)
In the current proposal, the investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the…
- Trial name
- NCT03842137
- Testing
- tDCS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Butler Hospital
Opioid-use Disorder
Buprenorphine Treatment Engagement and Overdose Prevention
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use…
- Trial name
- NCT03677986
- Testing
- Video DOT+
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Johns Hopkins University
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Drug Effect, Rib Fractures
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
Rib fractures represent a common injury pattern this is highly associated with patient morbidity and mortality, as pain control remains a challenge.
- Conditions
- Drug Effect, Rib Fractures, Rib Trauma, Surgical Procedure, Unspecified
- Trial name
- NCT03305666
- Testing
- Liposomal bupivacaine injection, Bupivacaine indwelling catheter
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Denver Health and Hospital Authority
Opioid Dependence
Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments
This study will compare the effects of brief strengths-based case management (SBCM) to the effects of screening, assessment and referral alone (SAR) in opioid-dependent patients.
- Trial name
- NCT02586896
- Testing
- Strengths-based Case Management (SBCM), Screening, Assessment, and Referral (SAR)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NYU Langone Health
Opioid Use Disorder, Chronic Pain
Phase II Pharmacokinetics Study of CAM2038
Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
- Trial name
- NCT02710526
- Testing
- CAM2038
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Improving Outcomes in Neonatal Abstinence Syndrome
1: SPECIFIC Aim I: To compare treatment options for neonatal abstinence syndrome (NAS) due to in-utero narcotic exposure. One hundred eighty four full-term infants with a diagnosis of NAS requiring medications will be studied.
- Trial name
- NCT01958476
- Testing
- Neonatal Morphine Solution, Methadone, Phenobarbital
- Where
- 8 sites in United States
- Volunteers
- 117 people
- Sponsor
- Tufts Medical Center
Naloxone
Increasing Naloxone Access for Persons Who Use Opioids
Deaths relating to opioid overdose have rapidly increased over the past two decades. Due to the serious public health concern of the opioid epidemic, federal agencies recommend employing various harm reduction interventions.
- Trial name
- NCT04303000
- Testing
- Opioid Overdose Education with Naloxone Distribution, Opioid Overdose Education
- Where
- 4 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Alabama at Birmingham
HIV Infections, Behavioral Symptoms
Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam
This project will adapt and pilot a feasible and effective problem-solving therapy designed for low-resource settings to address common mental disorders like depression and anxiety - the Friendship Bench- in a Vietnamese…
- Conditions
- HIV Infections, Behavioral Symptoms, Depression, Anxiety
- Trial name
- VITAL (NCT04790201)
- Testing
- Friendship Bench Delivered by Professional Counselor, Friendship Bench Delivered by Lay Counselor, Enhanced Usual Care
- Where
- Vietnam
- Volunteers
- 77 people
- Sponsor
- University of North Carolina, Chapel Hill
Pruritus
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
The purpose of this study is determine if long acting antihistamine like cetirizine can help with itching induced by opioid pain medications.
- Trial name
- NCT01825655
- Testing
- Cetirizine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Virginia Commonwealth University
Cocaine Dependence, Opiate Dependence
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
The main goal of this study is to evaluate the safety and tolerability of 40 or 80 mg atomoxetine as a treatment for cocaine dependence.
- Trial name
- NCT01802515
- Testing
- Atomoxetine, low dose, Atomoxetine, high dose
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Opioid Abuse, Opioid Dependence
Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
The overall goal of this project is to develop initial human data on effects of novel compounds on safety (interactions with oxycodone) and efficacy (subjective response to oxycodone) in non-treatment seeking opioid use disorder…
- Conditions
- Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
- Trial name
- NCT03143855
- Testing
- Lorcaserin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Virginia Commonwealth University
Opiate Dependence
A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment
The purpose of this study is to evaluate the effectiveness of the Therapeutic Workplace in promoting methadone treatment and increasing abstinence in unemployed, out-of-treatment injection heroine users.
- Trial name
- NCT01416584
- Testing
- methadone contingency, Methadone & Abstinence Contingency
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Johns Hopkins University
Opiate Dependence
Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment
The purpose of the study is to determine whether a change in the rules and staff roles in methadone treatment programs will result in greater lengths of stay in treatment and lower rates of heroin and cocaine use, crime and…
- Trial name
- NCT01442493
- Testing
- Patient-Centered Methadone Treatment, Methadone Treatment as usual
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Friends Research Institute, Inc.
Opioid-related Disorders
Abuse Liability of Suboxone Versus Subutex
The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT00710385
- Testing
- Heroin, Naloxone, Low Bup Dose
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid Dependence
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
The primary objective of this study is to compare overall patient preference for either Suboxone® sublingual film 8/2 or Zubsolv® sublingual tablets 5.7/1.4.
- Trial name
- NCT02038790
- Testing
- Suboxone Sublingual Film, Zubsolv sublingual tablets
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder, Infectious Disease
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of…
- Conditions
- Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use
- Trial name
- ACTION (NCT05286879)
- Testing
- Patient Navigator, Mobile Health Unit
- Where
- 3 sites in United States
- Volunteers
- 601 people
- Sponsor
- Yale University
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01323790
- Testing
- NKTR-118
- Where
- 120 sites in United States, Belgium and 6 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca